Effects of Bifidobacterium Longum Subsp. Infantis i18 on Gut Microbiota Development and Health in Early Life (Bifido i18)
Effects of Bifidobacterium Longum Subsp. Infantis i18 Intervention on Early-Life Gut Microbiota Development and Health Outcomes: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Study
This study aims to evaluate the effects of Bifidobacterium longum subsp. infantis i18 supplementation on symptoms, gut microbiota development, and overall health outcomes in healthy infants and young children in China.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jie Yuan
- 전화번호: +86 19821872781
- 이메일: 19821872781@163.com
연구 장소
-
-
Hebei
-
Zhangjiakou, Hebei, 중국
- First Hospital Hebei North University
-
연락하다:
- Erwei Yuan
- 전화번호: +86 13301878331
- 이메일: 13301878331@163.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
For the Probiotic and Placebo Groups:
- Healthy infants and young children aged 0-36 months at enrollment, born at 37-42 weeks of gestation with a birth weight of 2500-4000 g, receiving formula feeding and/or mixed feeding.
- Classified as being at high risk according to the study-defined assessment criteria.
- No clinically diagnosed allergic disease at enrollment.
- Written informed consent provided by the legal guardian.
For the Observational Reference Group:
- Healthy infants aged 0-6 months at enrollment, born at 37-42 weeks of gestation with a birth weight of 2500-4000 g, exclusively breastfed.
- Classified as being at high risk according to the study-defined assessment criteria.
- No clinically diagnosed allergic disease at enrollment.
- Written informed consent provided by the legal guardian.
Exclusion Criteria:
- Maternal history of metabolic or infectious diseases.
- High-risk pregnancy, or maternal history of alcohol, drug, or other substance abuse during pregnancy.
- Antibiotic use within 4 weeks before enrollment.
- Probiotic product use within 4 weeks before enrollment; for infants younger than 1 month, any use since birth.
- Immunosuppressive therapy before enrollment.
- Acute or chronic disease within 4 weeks before enrollment that may significantly affect growth and development.
- Congenital malformations or birth defects.
- Malnutrition requiring hospitalization.
- Known allergy to any component of the study probiotic product.
- Participation in another clinical trial or use of any investigational drug within 3 months before screening; for infants younger than 3 months, any such participation or use since birth.
- Any other condition considered by the investigator to potentially affect participant safety or interpretation of study data.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: 플라시보 그룹
|
Matching placebo without the probiotic intervention |
|
실험적: 프로바이오틱스 그룹
|
Bifidobacterium longum subsp. infantis i18 supplementation. |
|
간섭 없음: Observational Reference Group
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Number of participants with newly reported allergic symptoms (atopic dermatitis/eczema etc.) as assessed with the structured allergy symptom questionnaire
기간: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Number of participants with newly reported respiratory symptoms (respiratory tract infection etc.) as assessed with the structured respiratory symptom questionnaire
기간: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
|
Number of participants with newly reported gastrointestinal symptoms (constipation etc.) as assessed with the structured gastrointestinal symptom questionnaire
기간: From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
|
Feeding pattern as assessed with the structured feeding questionnaire
기간: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
|
Growth and nutritional status: body weight (kg), length/height (cm) and head circumference (cm) measured with a calibrated scale, infantometer/stadiometer and measuring tape, with age- and sex-adjusted Z-scores per WHO Child Growth Standards
기간: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
|
Gut microbiota composition and diversity: relative abundance (%), alpha diversity and beta diversity in faecal samples assessed by metagenomic sequencing.
기간: From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), faecal samples collected at each scheduled study visit.
|
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), faecal samples collected at each scheduled study visit.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- DICT-2026-01-03
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .